Network-based drugs and biomarkers

Journal of Pathology

Volumn 220, Issue 2, 2010, Pages 290-296

  Erler, Janine T ^a   Linding, Rune ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Biomarker; Drug; Gene; Network; Signalling; Systems biology; Treatment

Indexed keywords

BIOLOGICAL MARKER; STRESS ACTIVATED PROTEIN KINASE;

CELLULAR STRESS RESPONSE; DIABETES MELLITUS; DISEASE COURSE; DNA SEQUENCE; DRUG DESIGN; DRUG TARGETING; FUNCTIONAL GENOMICS; GENE MUTATION; GENE TARGETING; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METASTASIS; MOLECULAR INTERACTION; NEOPLASM; NETWORK LEARNING; PHENOTYPE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; DRUG DISCOVERY; HUMANS; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; SIGNAL TRANSDUCTION; SYSTEMS BIOLOGY;

EID: 73949157882     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.2646     Document Type: Review

References (47)

1. Shendure J, Mitra RD, Varma C, Church GM. Advanced sequencing technologies: methods and goals. Nat Rev Genet 2004;5:335-344.
2. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068.
3. Ong SE, Mann M. Mass spectrometry-based proteomics turns quantitative. Nat Chem Biol 2005;1:252-262.
4. Jørgensen C, Linding R. Directional and quantitative phosphorylation networks. Brief Funct Genom Proteom 2008;7:17-26.
5. Miller-Jensen K, Janes KA, Brugge JS, Lauffenburger DA. Common effector processing mediates cell-specific responses to stimuli. Nature 2007;448:604-608.
6. Spencer SL, Gaudet S, Albeck JG, Burke JM, Sorger PK. Nongenetic origins of cell-to-cell variability in TRAIL-induced apoptosis. Nature 2009;459:428-432.
7. Janes KA, Albeck JG, Gaudet S, Sorger PK, Lauffenburger DA, Yaffe MB. A systems model of signaling identifies a molecular basis set for cytokine-induced apoptosis. Science 2005;310: 1646-1653.
8. Janes KA, Yaffe MB. Data-driven modelling of signal-transduction networks. Nat Rev Mol Cell Biol 2006;7:820-828.
9. Seet BT, Dikic I, Zhou MM, Pawson T. Reading protein modifications with interaction domains. Nat Rev Mol Cell Biol 2006;7:473-483.
10. Miller ML, Jensen LJ, Diella F, Jørgensen C, Tinti M, Li L, et al. Linear motif atlas for phosphorylation-dependent signalling. Sci Signal 2008;1:ra2.
11. Linding R, Jensen LJ, Ostheimer GJ, van Vugt MA, Jørgensen C, Miron IM, et al. Systematic discovery of in vivo phosphorylation networks. Cell 2007;129:1415-1426.
12. Bakal C, Linding R, Llense F, Heffern E, Martin-Blanco E, Pawson T, et al. Phosphorylation networks regulating JNK activity in diverse genetic backgrounds. Science 2008;322:453-456.
13. Kumar N, Hendriks BS, Janes KA, de Graaf D, Lauffenburger DA. Applying computational modeling to drug discovery and development. Drug Discov Today 2006;11:806-811.
14. Aldridge BB, Saez-Rodriguez J, Muhlich JL, Sorger PK, Lauffenburger DA. Fuzzy logic analysis of kinase pathway crosstalk in TNF/EGF/insulin-induced signaling. PLoS Comput Biol 2009;5:e1000340.
15. Taylor IW, Linding R, Warde-Farley D, Liu Y, Pesquita C, Faria D, et al. Dynamic modularity in protein interaction networks predicts breast cancer outcome. Nat Biotechnol 2009;27:199-204.
16. Tan CS, Bodenmiller B, Pasculescu A, Jovanovic M, Hengartner MO, Jørgensen C, et al. Comparative analysis reveals conserved protein phosphorylation networks implicated in multiple diseases. Sci Signal 2009;2:ra39.
17. Tan CS, Pasculescu A, Lim WA, Pawson T, Bader GD, Linding R. Positive selection of tyrosine loss in metazoan evolution. Science 2009;325:1686-1688.
18. Pawson T, Linding R. Network Medicine. FEBS Lett 2008;582: 1266-1270.
19. Levy ED, Landry CR, Michnick SW. How perfect can protein interactomes be? Sci Signal 2009;2:pe11.
20. Bakal C, Aach J, Church G, Perrimon N. Quantitative morphological signatures define local signaling networks regulating cell morphology. Science 2007;316:1753-1756.
21. Wolf-Yadlin A, Hautaniemi S, Lauffenburger DA, White FM. Multiple reaction monitoring for robust quantitative proteomic analysis of cellular signaling networks. Proc Natl Acad Sci USA 2007;104:5860-5865.
22. Huang PH, Mukasa A, Bonavia R, Flynn RA, Brewer ZE, Cavenee WK, et al. Proc Natl Acad Sci USA 2007;104:12867-12872.
23. Schoeberl B, Pace EA, Fitzgerald JB, Harms BD, Xu L, Nie L, et al. Therapeutically targeting ErbB3: a key node in ligandinduced activation of the ErbB receptor-PI3K axis. Sci Signal 2009;2:ra31.
24. Ratushny V, Astsaturov I, Burtness BA, Golemis EA, Silverman JS. Targeting EGFR resistance networks in head and neck cancer. Cell Signal 2009;21:1255-1268.
25. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets 2009;13:339-362.
26. Campillos M, Kuhn M, Gavin AC, Jensen LJ, Bork P. Drug target identification using side-effect similarity. Science 2008;321: 263-266.
27. Ideker T, Sharan R. Protein networks in disease. Genome Res 2008;18:644-652.
28. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007;3:141.
29. Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA. Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol Cancer Ther 2009;8:2183-2192.
30. Steeg PS. Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 2006;12:895-904.
31. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006;127:679-695.
32. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
33. Paget S. The distribution of secondary growths in cancer of the breast. Cancer Metast Rev 1989;8:98-101.
34. Erler JT, Weaver VM. Three-dimensional context regulation of metastasis. Clin Exp Metast 2009;26:35-49.
35. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metast 2009;26:19-34.
36. Cairns RA, Khokha R, Hill RP. Molecular mechanisms of tumor invasion and metastasis: an integrated view. Curr Mol Med 2003;3:659-671.
37. Erler JT, Bennewith KL, Nicolau M, Dornḧofer N, Kong C, Le QT, et al. Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 2006;440:1222-1226.
38. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, et al. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche. Cancer Cell 2009;15:35-44.
39. WeigeltB, LoAT, ParkCC, GrayJW, BissellMJ. HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 2009;(in press).
40. Kenny PA, Lee GY, Myers CA, Neve RM, Semeiks JR, Spellman PT, et al. The morphologies of breast cancer cell lines in three-dimensional assays correlate with their profiles of gene expression. Mol Oncol 2007;1:84-96.
41. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003;3:921-930.
42. Friedl P. Dynamic imaging of cancer invasion and metastasis: principles and preclinical applications. Clin Exp Metast 2009;26:269-271.
43. Sahai E. Illuminating the metastatic process. Nat Rev Cancer 2007;7:737-749.
44. Geyer FC, Marchio C, Reis-Filho JS. The role of molecular analysis in breast cancer. Pathology 2009;41:77-88.
45. Barabási AL. Network medicine - from obesity to the 'diseasome'. N Engl J Med 2007;357:404-407.
46. Brehme M, Hantschel O, Colinge J, Kaupe I, Planyavsky M, Köcher T, et al. Charting the molecular network of the drug target Bcr-Abl. Proc Natl Acad Sci USA 2009;106:7414-7419.
47. Henney A, Superti-Furga G. A network solution. Nature 2008; 455:730-731.